125 related articles for article (PubMed ID: 23813283)
1. Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.
Dai JY; Li SS; Gilbert PB
Biostatistics; 2014 Jan; 15(1):196-203. PubMed ID: 23813283
[TBL] [Abstract][Full Text] [Related]
2. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
Juraska M; Gilbert PB
Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
[TBL] [Abstract][Full Text] [Related]
3. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.
Gilbert PB
Stat Med; 2000 Nov; 19(22):3065-86. PubMed ID: 11113943
[TBL] [Abstract][Full Text] [Related]
4. Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.
Sun Y; Li M; Gilbert PB
Biostatistics; 2013 Jan; 14(1):60-74. PubMed ID: 22764174
[TBL] [Abstract][Full Text] [Related]
5. Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy Trials.
Yang G; Sun Y; Qi L; Gilbert PB
Stat Biosci; 2017 Jun; 9(1):259-283. PubMed ID: 28781713
[TBL] [Abstract][Full Text] [Related]
6. Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials.
Sun Y; Qi L; Yang G; Gilbert PB
Biom J; 2018 May; 60(3):516-536. PubMed ID: 29488249
[TBL] [Abstract][Full Text] [Related]
7. Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark.
Sun Y; Li M; Gilbert PB
Comput Stat Data Anal; 2016 Jan; 93():348-358. PubMed ID: 26461462
[TBL] [Abstract][Full Text] [Related]
8. Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy.
Gilbert PB
Stat Med; 2001 Jan; 20(2):263-79. PubMed ID: 11169601
[TBL] [Abstract][Full Text] [Related]
9. Mark-specific hazard ratio model with missing multivariate marks.
Juraska M; Gilbert PB
Lifetime Data Anal; 2016 Oct; 22(4):606-25. PubMed ID: 26511033
[TBL] [Abstract][Full Text] [Related]
10. Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.
Gilbert P; Self S; Rao M; Naficy A; Clemens J
J Clin Epidemiol; 2001 Jan; 54(1):68-85. PubMed ID: 11165470
[TBL] [Abstract][Full Text] [Related]
11. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
Gilbert PB; McKeague IW; Sun Y
Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
[TBL] [Abstract][Full Text] [Related]
12. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
[TBL] [Abstract][Full Text] [Related]
13. PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.
Sun Y; Gilbert PB; McKeague IW
Ann Stat; 2009 Feb; 37(1):394-426. PubMed ID: 19838313
[TBL] [Abstract][Full Text] [Related]
14. Sieve analysis in HIV-1 vaccine efficacy trials.
Edlefsen PT; Gilbert PB; Rolland M
Curr Opin HIV AIDS; 2013 Sep; 8(5):432-6. PubMed ID: 23719202
[TBL] [Abstract][Full Text] [Related]
15. Semiparametric regression on cumulative incidence function with interval-censored competing risks data.
Bakoyannis G; Yu M; Yiannoutsos CT
Stat Med; 2017 Oct; 36(23):3683-3707. PubMed ID: 28608412
[TBL] [Abstract][Full Text] [Related]
16. Joint inferences on vaccine efficacy against infection and disease with application to the first HIV vaccine efficacy trial.
Cai T; Gilbert PB; Self SG
J Biopharm Stat; 2006; 16(4):517-38. PubMed ID: 16892911
[TBL] [Abstract][Full Text] [Related]
17. CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.
Dommaraju K; Kijak G; Carlson JM; Larsen BB; Tovanabutra S; Geraghty DE; Deng W; Maust BS; Edlefsen PT; Sanders-Buell E; Ratto-Kim S; deSouza MS; Rerks-Ngarm S; Nitayaphan S; Pitisuttihum P; Kaewkungwal J; O'Connell RJ; Robb ML; Michael NL; Mullins JI; Kim JH; Rolland M
PLoS One; 2014; 9(10):e111334. PubMed ID: 25350851
[TBL] [Abstract][Full Text] [Related]
18. Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks.
Sun Y; Gilbert PB
Scand Stat Theory Appl; 2012 Mar; 39(1):34-52. PubMed ID: 23519918
[TBL] [Abstract][Full Text] [Related]
19. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
Gilbert PB; Self SG; Ashby MA
Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Gray GE; Allen M; Moodie Z; Churchyard G; Bekker LG; Nchabeleng M; Mlisana K; Metch B; de Bruyn G; Latka MH; Roux S; Mathebula M; Naicker N; Ducar C; Carter DK; Puren A; Eaton N; McElrath MJ; Robertson M; Corey L; Kublin JG;
Lancet Infect Dis; 2011 Jul; 11(7):507-15. PubMed ID: 21570355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]